A Unique Situation For UniQure
Source: SeekingAlpha
2026-03-12 14:20:00 ET
Let’s have a look at the unique situation of UniQure ( QURE ). It’s a story about central nervous system disease therapy, that’s for sure. And it’s a story about clinical trial design, and it’s also a story about new and challenging modes of treatment working their way into such human trials. But unfortunately, it has turned most of all into a story about regulatory affairs as they are run under the Trump administration....
Read the full article on Seeking Alpha
For further details see:
A Unique Situation For UniQure
uniQure N.V.
NASDAQ: QURE
QURE Trading
-2.98% G/L:
$19.438 Last:
653,099 Volume:
$19.85 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
